Diagnosis of narcolepsy (NT1 or NT2) or IH who was eligible for and completed the full treatment period in the eligible parent study ORX750-0201 (CRYSTAL-1)
Is willing and able to adhere to additional protocol requirements
You may not be if
Development of any new disease/disorder that in the opinion of the investigator would make the participant unable to continue the study
Unable to refrain from excluded medications, including those used for treatment of narcolepsy or idiopathic hypersomnia
Clareo Health | A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
